CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0813 (clinicaltrials.gov NCT No: NCT00422591)
Title:Prospective evaluation of standard chemotherapy regimen of Idarubicin and Cytarabine in patients with newly diagnosed acute myeloid leukemia (AML)
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Cytarabine; Idarubicin
Study Status:Closed
Study Description:The goal of this clinical research study is to find out if standard
chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control
AML.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cytarabine
Idarubicin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:7 to 28 days
Supported By:N/A
Return Visit:2 to 3 times weekly for the first 2 months, then weekly while receiving therapy
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
Dept:Leukemia
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults